Royal London Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$142M Buy
1,810,815
+200,262
+12% +$13.7M 0.26% 75
2026
Q1
$104M Buy
1,610,553
+239,282
+17% +$16.9M 0.22% 97
2025
Q4
$92.3M Buy
1,371,271
+228,014
+20% +$15.3M 0.19% 104
2025
Q3
$83.8M Buy
1,143,257
+41,345
+4% +$2.75M 0.18% 113
2025
Q2
$57.3M Buy
1,101,912
+606,236
+122% +$34.5M 0.13% 152
2025
Q1
$31.6M Buy
+495,676
New +$28.8M 0.07% 232

Other funds holding HALO

Royal London Asset Management's HALO Position: Q2 2026 in Review

Royal London Asset Management increased its Halozyme (HALO) stake by 12% in Q2 2026, buying an estimated $13.7M and bringing the position to 1,810,815 shares worth $142M. The position accounts for 0.26% of the portfolio, ranked #75.

Royal London Asset Management first reported a position in HALO in Q1 2025 and has held it in 6 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Royal London Asset Management held 1,810,815 shares of Halozyme worth $142M as of Q2 2026.
  • Royal London Asset Management bought 200,262 Halozyme shares in Q2 2026, an estimated $13.7M.
  • Halozyme made up 0.26% of Royal London Asset Management's portfolio in Q2 2026, its #75 holding.
  • Royal London Asset Management first reported a position in Halozyme in Q1 2025 and has held it in 6 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.